Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk
18-Dec-2003
"We are pleased that Novo Nordisk chose our HAP(TM) Technology to address their pharmacogenomic need," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Novo Nordisk has been utilizing our Good Laboratory Practices DNA and genotyping services and this agreement expands the scope of our work with them, demonstrating how our various pharmacogenomic capabilities can benefit our customer base."
Topics
Organizations
Genaissance Pharmaceuticals
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.